EDITAS MEDICINE INC.

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

07 يونيو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

06 يونيو 2022 16:30:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

18 مايو 2022 06:45:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

12 مايو 2022 16:30:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

04 مايو 2022 13:30:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2022 Results and Business Updates

04 مايو 2022 06:45:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

02 مايو 2022 16:31:07 بحسب Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

27 أبريل 2022 06:55:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

26 أبريل 2022 09:00:03 بحسب Nasdaq GlobeNewswire

Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer

14 أبريل 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

11 أبريل 2022 09:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

08 أبريل 2022 13:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

28 فبراير 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

24 فبراير 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

16 فبراير 2022 06:15:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

10 يناير 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 يناير 2022 06:58:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

20 ديسمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

12 ديسمبر 2021 18:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

12 نوفمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire